David Barras

University Hospital of Lausanne — Switzerland

Medicine · Health Sciences

27h-index8.2kcitations123works29.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(41), Immunotherapy and Immune Responses(29), Colorectal Cancer Treatments and Studies(24), Genetic factors in colorectal cancer(18), CAR-T cell therapy research(18)

Publications122 total

Computational Inference of Metabolic Programs: A Case Study Analyzing the Effect of BRCA1 Loss
2025Open Access
Tissue specificity and chromosomal alterations shape divergent immune programs in HRD tumors
2025Open Access
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer
Cancer Cell·2025· 10 citedOpen Access
Combinatorial delivery of low-dose irradiation and immunotherapy to patients with immune-excluded tumors effectively enhances CD8 <sup>+</sup> T cell functionality
2025Open Access
Zinc availability in the tumor microenvironment dictates anti-PD1 response in <i>CDKN2A</i> <sup>Low</sup> tumors via increased macrophage phagocytosis
2025· 3 citedOpen Access
Cancer cells impair monocyte-mediated T cell stimulation to evade immunity
Nature·2024· 87 citedOpen Access
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma
Immunity·2024· 36 cited
Predicting Antigen‐Specificities of Orphan T Cell Receptors from Cancer Patients with TCRpcDist
Advanced Science·2024· 6 citedOpen Access
Author Correction: Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms
Nature Biotechnology·2024· 4 citedOpen Access
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms
Nature Biotechnology·2024· 28 citedOpen Access
Myeloid cell networks determine reinstatement of original immune environments in recurrent ovarian cancer
2024· 2 citedOpen Access
PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function
Nature·2024· 164 citedOpen Access
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 <sup>+</sup> T-myeloid cell networks in melanoma
Science Immunology·2024· 72 citedOpen Access
Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signatures
2024· 4 citedOpen Access
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer
Nature Cancer·2023· 20 citedOpen Access
Tumor-reactive clonotype dynamics underlying clinical response to TIL therapy in melanoma
2023· 8 citedOpen Access
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors
Nature Communications·2023· 63 citedOpen Access
Supplementary Table from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
2023Open Access
Supplementary Table from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
2023Open Access
Supplementary Figure from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
2023Open Access
page 1 of 7Next →

Frequent Co-authors

George Coukos(21), Denarda Dangaj Laniti(20), Mauro Delorenzi(19), Lana E. Kandalaft(14), Alexandre Harari(12), Fabrizio Benedetti(11), Sara Bobisse(11), Michal Bassani‐Sternberg(11), Johanna Chiffelle(9), Alizée J Grimm(8), Raphaël Genolet(8), Noémie Fahr(8), Olivier Michielin(8), Christian Widmann(8), Sylvie Rusakiewicz(7), Marion Arnaud(7), Eleonora Ghisoni(7), Rémy Pétremand(7), Krisztián Homicskó(6), Sabine Tejpar(6)